In this study, we describe a genetic alteration that enhances DLBCL vulnerability to BCL2 inhibitors and propose a mechanistic rationale for combining BCL2 inhibitors with the HDAC inhibitor panobinostat for the treatment of DLBCL. Here, HDAC9 is linked to diffuse large B-cell lymphoma.